These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Motor dysfunction after spinal cord injury is mediated by opiate receptors. Faden AI; Knoblach S; Mays C; Jacobs TP Peptides; 1985; 6 Suppl 1():15-7. PubMed ID: 2995941 [TBL] [Abstract][Full Text] [Related]
3. Naloxone in experimental spinal cord ischemia: dose-response studies. Faden AI; Jacobs TP; Smith MT; Zivin JA Eur J Pharmacol; 1984 Aug; 103(1-2):115-20. PubMed ID: 6479224 [TBL] [Abstract][Full Text] [Related]
4. Role of thyrotropin-releasing hormone and opiate receptor antagonists in limiting central nervous system injury. Faden AI Adv Neurol; 1988; 47():531-46. PubMed ID: 2830771 [TBL] [Abstract][Full Text] [Related]
5. New pharmacologic approaches to spinal cord injury: opiate antagonists and thyrotropin-releasing hormone. Faden AI Cent Nerv Syst Trauma; 1985; 2(1):5-8. PubMed ID: 3004747 [No Abstract] [Full Text] [Related]
6. Comparison of the neuroprotective effects of the N-methyl-D-aspartate antagonist MK-801 and the opiate-receptor antagonist nalmefene in experimental spinal cord ischemia. Yum SW; Faden AI Arch Neurol; 1990 Mar; 47(3):277-81. PubMed ID: 2178593 [TBL] [Abstract][Full Text] [Related]
7. Opiate-receptor antagonist nalmefene improves neurological recovery after traumatic spinal cord injury in rats through a central mechanism. Faden AI; Sacksen I; Noble LJ J Pharmacol Exp Ther; 1988 May; 245(2):742-8. PubMed ID: 3367315 [TBL] [Abstract][Full Text] [Related]
8. Treatment of experimental stroke with the opiate antagonist win 44,441-3 effects on neurologic function, infarct size, and survival. Baskin DS; Hosobuchi Y NIDA Res Monogr; 1986; 75():531-4. PubMed ID: 3123973 [TBL] [Abstract][Full Text] [Related]
12. Limiting ischemic spinal cord injury using a free radical scavenger 21-aminosteroid and/or cerebrospinal fluid drainage. Francel PC; Long BA; Malik JM; Tribble C; Jane JA; Kron IL J Neurosurg; 1993 Nov; 79(5):742-51. PubMed ID: 8410254 [TBL] [Abstract][Full Text] [Related]
13. Neuropeptides in spinal cord injury: comparative experimental models. Faden AI; Jacobs TP; Smith GP; Green B; Zivin JA Peptides; 1983; 4(5):631-4. PubMed ID: 6657511 [TBL] [Abstract][Full Text] [Related]
14. Levels of endogenous opioids and effects of an opiate antagonist during regional cerebral ischemia in rats. Andrews BT; McIntosh TK; Gonzales MF; Weinstein PR; Faden AI J Pharmacol Exp Ther; 1988 Dec; 247(3):1248-54. PubMed ID: 3204516 [TBL] [Abstract][Full Text] [Related]
15. Neuropeptides and central nervous system injury. Clinical implications. Faden AI Arch Neurol; 1986 May; 43(5):501-4. PubMed ID: 2870700 [TBL] [Abstract][Full Text] [Related]
16. Endogenous opioids may mediate secondary damage after experimental brain injury. McIntosh TK; Hayes RL; DeWitt DS; Agura V; Faden AI Am J Physiol; 1987 Nov; 253(5 Pt 1):E565-74. PubMed ID: 2891303 [TBL] [Abstract][Full Text] [Related]
17. Intrathecal transplantation of bone marrow stromal cells attenuates blood-spinal cord barrier disruption induced by spinal cord ischemia-reperfusion injury in rabbits. Fang B; Wang H; Sun XJ; Li XQ; Ai CY; Tan WF; White PF; Ma H J Vasc Surg; 2013 Oct; 58(4):1043-52. PubMed ID: 23478501 [TBL] [Abstract][Full Text] [Related]
18. Opiate-receptor antagonists, thyrotropin-releasing hormone (TRH), and TRH analogs in the treatment of spinal cord injury. Faden AI Cent Nerv Syst Trauma; 1987; 4(4):217-26. PubMed ID: 3128405 [No Abstract] [Full Text] [Related]